Multiple myeloma (MM) is an incurable cancer characterized by a high concentration of clonal malignant B cell population in the bone marrow. Despite the recent advances in relapsed or refractory MM treatment, the prognosis of the patients remain poor as the depth and duration of response to current therapies diminish over time and the disease inevitably becomes refractory. This study aims to characterize MM patient population and to describe current treatment practices in advanced MM.
